Coeptis Therapeutics Holdings (COEP) has issued an announcement.
The Company’s Compensation Committee and Board of Directors have approved a significant incentive for CEO David Mehalick, awarding him options to acquire 2.4 million shares at the closing price on the date of approval, vested immediately with a 10-year term. Additionally, the firm announced the successful closure of their Series A Preferred sale in a recent press release.
See more data about COEP stock on TipRanks’ Stock Analysis page.